Meeting
2023 ASCO Genitourinary Cancers Symposium
Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).
Presenter
Brian M. Shuch, MD
Institute of Urologic Oncology, David Geffen School of Medicine at UCLA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session C: Renal and Rare Tumors
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT03849118
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr LBA602)
DOI
10.1200/JCO.2023.41.6_suppl.LBA602
Abstract #
LBA602
Abstract Disclosures
Similar Videos & Slides
Speaker: Aaron Lyss, MBA
Videos & Slides
2024 ASCO Annual Meeting
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.
Speaker: Maria T. Bourlon, MD, MSc
Videos & Slides
2024 ASCO Annual Meeting
Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.
Speaker: Saby George, MD, FACP
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
Speaker: Toni K. Choueiri, MD, FASCO